Neoadjuvant nivolumab shows long-term benefit in patients with non–small cell lung cancer (“Major pathologic response”)

Medical Xpress / American Association for Cancer Research / Clinical Cancer Research ^ | Feb. 15, 2023 | Samuel Rosner et al

[ConservativeMind]

Patients with resectable non–small cell lung cancer (NSCLC) who were treated with neoadjuvant nivolumab had improved five-year recurrence-free and overall survival rates compared with historical outcomes, according to results.

Forde, Rosner, and colleagues previously reported safety and efficacy results from a phase II clinical trial in which patients with stage I-III resectable NSCLC were treated with two doses of neoadjuvant nivolumab. Major pathological responses were observed in 45% of patients, independent of tumor PD-L1 expression, and 73% of patients whose tumors were surgically resected were recurrence-free 18 months following surgery.

The latest publication reports the final analyses from this trial, including five-year recurrence-free and overall survival rates for the 20 patients who underwent surgical resection.

Among the 20 patients who underwent surgical resection, 12 patients (60%) remained recurrence-free five years after surgery, and 16 patients (80%) were alive, exceeding the 36% to 68% five-year survival rate historically observed for patients with stage I-III NSCLC, Rosner noted. Forde added that the observed patient outcomes after neoadjuvant nivolumab were better than those historically observed among patients treated with neoadjuvant chemotherapy.

The authors also identified major pathologic response after neoadjuvant nivolumab as a potential predictive biomarker of recurrence-free and overall survival. Of the nine patients who had a major pathological response after neoadjuvant nivolumab, eight were alive and cancer-free five years after treatment. One patient experienced a recurrence within the first 10 months after treatment but has since been disease-free after definitive chemoradiation. The one death in this subgroup was unrelated to cancer.

Neoadjuvant nivolumab did not lead to surgical delays, and there was only one late-onset immune-related adverse event, which occurred 16 months after nivolumab treatment and was successfully managed, the authors noted.

"The results from the five-year follow-up analysis indicate that neoadjuvant nivolumab was safe in long-term follow-up," said Forde.

[ConservativeMind]

This therapy is available, today.

[ConservativeMind]

The “Take Charge Of Your Health” Ping List
This high volume ping list is for health articles and studies which describe something you or your doctor, when informed, may be able to immediately implement for your benefit.

Email me to get on either the “Common/Top Issues” (20 - 25% fewer pings) or “Everything” list.

[surroundedbyblue]

Heads up that any -mab ending pharmaceutical is created from fully humanized mice. You can use your imagination as to how those mice became humanized.

There’s a reason that abortion is highly profitable

[Celerity]

Also, the core of this report is findings from the pharmaceutical creator, bristol-myers squibb.

[Celerity]

It’s also the reason my daughter’s mother is alive.

This is a tough argument.. not everything is black and white.

Crohns disease has only a few options. These -mab drugs have extended those options and far less people are dying.

Medical experimentation and treatments are never a simple matter.

I’m not against you, I’m just saying that anyone who may disagree isn’t a fool either.

[Irish Eyes]

Bookmark